The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease
Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country comparison of the results of the CUA and BIA and detail...
Saved in:
Main Authors: | Jesper Jørgensen (Author), Spiros Servos (Author), Panos Kefalas (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test
by: Jesper Jørgensen, et al.
Published: (2017) -
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
by: Jesper Jørgensen, et al.
Published: (2019) -
Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching
by: Jesper Jørgensen, et al.
Published: (2019) -
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020) -
Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds
by: Paul Langley
Published: (2018)